EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

MAP1LC3C repression reduces CIITA- and HLA class II expression in non-small cell lung cancer

Lydie M O Barbeau, Nicky A Beelen, Kim G Savelkouls, Tom G H Keulers, Lotte Wieten, Kasper M A Rouschop iD

PLOS ONE · 10.02.2025 · 20 (2) · e0316716

DOI: 10.1371/journal.pone.0316716 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 10.02.2025. Verfasst von Lydie M O Barbeau und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology (Maastro), GROW - School for Oncology and Reproduction, Maastricht University Medical Center+, Maastricht, The Nethe…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Microtubule-Associated Proteins, Histocompatibility Antigens Class II. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: KWF Kankerbestrijding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the last decade, advancements in understanding the genetic landscape of lung squamous cell carcinoma (LUSC) have significantly impacted therapy development. Immune checkpoint inhibitors (ICI) have shown great promise, improving overall and progression-free survival in approximately 25% of the patients. However, challenges remain, such as the lack of predictive biomarkers, difficulties in patient stratification, and identifying mechanisms that cancers use to become immune-resistant (“immune-cold”). Analysis of TCGA datasets reveals reduced MAP1LC3C expression in cancer. Further analysis indicates that low MAP1LC3C is associated with reduced CIITA and HLA expression and with decreased immune cell infiltration. In tumor cells, silencing MAP1LC3C inhibits CIITA expression and suppresses HLA class II production. These findings suggest that cancer cells are selected for low MAP1LC3C expression to evade efficient immune responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsMicrotubule-Associated ProteinsHistocompatibility Antigens Class IINuclear ProteinsTrans-ActivatorsHumansGene Expression Regulation, NeoplasticCell Line, Tumor

Substanzen

MHC class II transactivator proteinMicrotubule-Associated ProteinsHistocompatibility Antigens Class IINuclear ProteinsTrans-Activators

Autor:innen und Institutionen

  • Department of Radiation Oncology (Maastro), GROW - School for Oncology and Reproduction, Maastricht University Medical Center+, Maastricht, The Netherlands.
  • Department of Internal Medicine, GROW - School for Oncology and Reproduction, Maastricht University Medical Center+, Maastricht, The Netherlands.
  • Department of Transplantation Immunology, GROW - School for Oncology and Reproduction, Maastricht University Medical Center+, Maastricht, The Netherlands.

ORCID-Profile: Kasper M A Rouschop

Förderung

  • KWF Kankerbestrijding

Zitieren

APA

Barbeau, L. M. O., Beelen, N. A., Savelkouls, K. G., Keulers, T. G. H., Wieten, L., & Rouschop, K. M. A. (2025). MAP1LC3C repression reduces CIITA- and HLA class II expression in non-small cell lung cancer. PLOS ONE, 20(2), e0316716. https://doi.org/10.1371/journal.pone.0316716

Vancouver

Barbeau LMO, Beelen NA, Savelkouls KG, Keulers TGH, Wieten L, Rouschop KMA. MAP1LC3C repression reduces CIITA- and HLA class II expression in non-small cell lung cancer. PLOS ONE. 2025;20(2):e0316716. doi:10.1371/journal.pone.0316716

BibTeX
@article{Barbeau2025,
  author = {Barbeau, Lydie M O and Beelen, Nicky A and Savelkouls, Kim G and Keulers, Tom G H and Wieten, Lotte and Rouschop, Kasper M A},
  title = {MAP1LC3C repression reduces CIITA- and HLA class II expression in non-small cell lung cancer},
  journal = {PLOS ONE},
  year = {2025},
  volume = {20},
  number = {2},
  pages = {e0316716},
  doi = {10.1371/journal.pone.0316716}
}
Kostenlos starten →